ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B)

Press/Media: Press / Media

PeriodApr 27 2015

Media coverage

24

Media coverage

  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% Of Post-Liver Transplant Patients With Hepatitis C And Up To 94% Of Hepatitis C Patients With Cirrhosis (Child-Pugh Class A Or B)
    Media name/outletTheStreet.com
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletRCL Advisors
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletSearchBug
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletWall Street Select
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletMarketplace
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletBioSpace
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletReliance Trust
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletFinancial Content
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletTown Hall
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletWall Street Business Network
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletTamar Securities
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen...
    Media name/outletFinwin
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver...
    Media name/outletStockhouse Canada
    CountryCanada
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletMyrtle Beach Sun News
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletGood Day Sacramento
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletAsk.com
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class
    Media name/outletStock Nod
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad